DS-7011a ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
49Systemic lupus erythematosus2

49. Systemic lupus erythematosus


Clinical trials : 993 Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05638802
(ClinicalTrials.gov)
March 202328/11/2022A Study of DS-7011a in Patients With Systemic Lupus Erythematosus and Cutaneous Lupus ErythematosusA Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety, Pharmacokinetics, and Proof of Biological Activity of DS-7011a in Patients With Systemic Lupus Erythematosus and Active Cutaneous Lupus ErythematosusSystemic Lupus Erythematosus;Cutaneous Lupus ErythematosusDrug: DS-7011a;Drug: PlaceboDaiichi Sankyo, Inc.NULLNot yet recruiting18 YearsN/AAll24Phase 1/Phase 2NULL
2NCT05203692
(ClinicalTrials.gov)
February 2, 202220/1/2022A Study of a Single Ascending Dose Study of DS-7011a in Healthy SubjectsA Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of DS-7011a in Healthy SubjectsSystemic Lupus ErythematosusDrug: DS-7011a;Drug: PlaceboDaiichi Sankyo, Inc.NULLActive, not recruiting18 Years45 YearsAll80Phase 1United States